News
Tofacitinib vs TNFi for RA: Safety Study Results Announced
The randomized phase 3b/4 ORAL Surveillance study included 4362 RA patients who were taking methotrexate without adequate control of symptoms.
Your search for tofacitinib returned 97 results
News
Xeljanz Approved for Active Polyarticular Course Juvenile Idiopathic Arthritis
Patients treated with tofacitinib experienced significantly fewer disease flares compared with placebo.
News
Recommendations Provided for Treatment of Ulcerative Colitis
Infliximab, adalimumab, golimumab, vedolizumab, tofacitinib, ustekinumab recommended over no tx
News
Successful Treatment of Long-Term Eosinophilic Esophagitis With JAK Inhibitor
Several treatments were attempted but failed to manage the patient’s conditions, including proton pump inhibitors, topical steroids, a restricted diet, and infliximab (3 doses) for arthritis.
Drug Monograph Updates
January 2020 Recap of Drug Updates
The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of January. The chart below provides highlights of key monograph updates made this month (not an inclusive list). Click on the name of the drugs to view the full monographs on eMPR.com. Key: D=Dosing,…
News
Xeljanz XR Approved for Ulcerative Colitis
The FDA has approved Xeljanz XR (tofacitinib extended-release; Pfizer) for the treatment of adult patients with moderately to severely active ulcerative colitis.
AIBD 2019
Worsening Symptoms, Heart Failure in UC Patient Treated With Mesalamine
The patient had been diagnosed with mild-to-moderate ulcerative colitis (UC) a month prior to presentation for which she was prescribed oral mesalamine.
AIBD 2019
Combination Biologics or Small Molecules vs Biologic Monotherapy in IBD
The following article is a part of conference coverage from the 2019 Advances in Inflammatory Bowel Diseases (AIBD) Meeting, being held in Orlando, Florida. The team at MPR will be reporting on the latest news and research conducted by leading experts gastroenterology. Check back for more from the 2019 AIBD Meeting. Combination biologic therapy may…
AIBD 2019
Timing of Biologic/JAK Inhibitor Treatment Initiation in IBD Patients Examined
According to new research over 1 in 5 patients with inflammatory bowel disease (IBD) should have started treatment with an advanced systemic therapy earlier in their disease.
AIBD 2019
Tofacitinib vs Vedolizumab: Short-Term Efficacy Compared in Ulcerative Colitis
In patients with ulcerative colitis (UC), tofacitinib, a Janus kinase inhibitor, was associated with improved short-term efficacy, when compared with vedolizumab, an integrin receptor antagonist. Findings were presented at the Advances in Inflammatory Bowel Disease (AIBD) 2019 meeting in Orlando, Florida.
